Intravitreous injection of melphalan can have toxic effects in the anterior eye segment in addition to well established effects in the posterior segment, a new study shows. Reuters Health Information
Uncategorized
RESPOND study: Iluvien effective at 6 months in DME patients
Iluvien was effective and well tolerated in reducing retinal thickness and improving visual acuity in patients with chronic diabetic macular edema, Alimera Sciences announced in a press release.Alimera Sciences Limited, the company’s European subsidiary, announced the interim 6-month results of the RESPOND study at the Euretina congress in Nice, France.
Bruker Introduces the rapifleX™ MALDI-TOF/TOF at HUPO
VANCOUVER, British Columbia–(BUSINESS WIRE)–At the 14th Human Proteome Organization World Congress (HUPO), Bruker today announced the new rapifleX MALDI-TOF/TOF mass spectrometer. MALDI-TOF/TOF is established as a powerful tandem mass spectrometry method for in-depth protein analysis. With its redesigned, next-generation TOF/TOF ion optics, the rapifleX system now offers significantly higher speed, mass resolution and mass accuracy. The rapifleX integrates a novel, 10 kHz smartbeam™ 3D scanni
Uncategorized
VIDEO: Retinal specialist dicusses treatment options for DME
NICE, France — At the Euretina meeting, Edoardo Midena, MD, discusses why a personalized approach is essential in deciding whether to use anti-VEGFs or steroids as first-line treatment for patients with diabetic macular edema.
ILUVIEN continues to show positive results in Europe
Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced the availability of real wor…
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for OpRegen®, a cell-based therapeutic product consisting of retinal pigment epithelial (RPE) cells designed to block the progression of the severe dry-form of age-related macular degeneration (AMD), a leading cause of blindness in an aging populatio